Abstract
Calciphylaxis is a rare and potentially fatal small-vessel occlusive disease in which the tunica media becomes calcified, endothelial cells proliferate, and the tunica intima becomes thickened and fibrotic. Calciphylaxis typically occurs in the setting of end-stage renal disease with secondary hyperparathyroidism and elevated calcium-phosphorus product. The estimated incidence of calciphylaxis in dialysis or kidney transplant patients is 1 to 4%; however, the incidence of non-uremic calciphylaxis is unknown. We assessed postmarketing adverse event reports to further characterize cases of calciphylaxis associated with teriparatide. We searched for cases of teriparatide-associated calciphylaxis in the literature (EMBASE, PubMed) and those reported to FDA, including the FDA Adverse Event Reporting System, through March 31, 2021. We included calciphylaxis cases following teriparatide exposure of < 2 years. Twelve cases described teriparatide-associated calciphylaxis. The median age was 81 (range 47–86) years. Eleven cases reported confirmatory biopsy and/or imaging. The median time-to-onset of calciphylaxis following teriparatide initiation was 3.5 (range 1–20) months. Three cases reported hospitalization, of which one resulted in death due to progression of the lesions. All cases had multiple risk factors (mean (SD), 4.5 (1.0)) including concomitant medications associated with calciphylaxis (12), female sex (11), and/or underlying autoimmune disease or other inflammatory disorder (10). We believe that exposure to teriparatide, coupled with underlying risk factors, may have triggered new-onset calciphylaxis. Expedited diagnosis and management by a clinician are important because calciphylaxis may be life-threatening and early intervention may improve outcomes.
Similar content being viewed by others
Data availability
Not applicable.
Code availability
Not applicable.
References
Kalajian AH, Malhotra PS, Callen JP et al (2009) Calciphylaxis with normal renal and parathyroid function. Arch Dermatol 145(4):451–458
Reiter N, El-Shabrawi L, Leinweber B et al (2011) Calcinosis cutis. Part I Diagnostic pathway. J Am Acad Dermatol 65:1–12
Nigwekar SU, Kroshinsky D, Nazarian RM et al (2015) Calciphylaxis: risk factors, diagnoses, and treatment. Am J Kidney Dis 66(1):133–146
Brandenburg VM, Cozzolino M, Ketteler M (2011) Calciphylaxis: a still unmet challenge. J Nephrol 24(2):142–148
Nigwekar SU, Solid CA, Ankers E et al (2014) Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med 29(Suppl 3):S724–S731
Nigwekar SU, Wolf M, Sterns RH et al (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 3:1139–1143
U.S. Food & Drug Administration. Questions and answers on FDA’s Adverse Event Reporting System (FAERS). June 4, 2018. Accessed on July 29, 2021 at https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers
Monegal A, Peris P, Alsina M et al (2016) Development of multiorganic calciphylaxis during teriparatide, vitamin D, and calcium treatment. Osteoporos Int 27:2631–2634
Leis-Dosil VM, Rubio-Flores C et al (2013) Cutaneous vascular calcifications secondary to treatment with teriparatide. Actas Dermosifiliogr 104:87–88
Spanakis EK, Sellmeyer DE (2014) Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment. Osteoporos Int 25:1411–1414
Dominguez AR, Goldman SE (2014) Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide. J Am Acad Dermatol 70(2):e41–e42
Forteo (teriparatide) [package insert]. Eli Lilly and Company. Indianapolis, IN. March 2012
Yu WYH, Bhutani T, Kornik R et al (2017) Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol 153(3):309–314
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, J., Konkel, K., Jones, S.C. et al. Teriparatide-associated calciphylaxis: a case series. Osteoporos Int 33, 499–504 (2022). https://doi.org/10.1007/s00198-021-06139-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-021-06139-3